Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL), a biopharmaceutical company focused on next-generation programmed T cell therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM EDT/1:30 PM BST featuring management's discussion of financial results and a business update. Participants must pre-register to receive dial-in details and a personal PIN for the call. A simultaneous audio webcast and replay will be available on the company's website events section.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
In the trading session that priced this news, AUTL declined 1.49%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025.
Management will host a conference call and webcast at 8:30am EDT/13:30pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
